Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • IQVIA AI Assistant
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Meet the IQVIA AI Assistant

Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Article
Understanding the Surge in New Product Launches in China's Pharma Market
How is Forecast Link leveraging the trend?
Jun 19, 2024
  • Library
  • Understanding the Surge in New Product Launches in China's Pharma Market
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

The drug approval process in China underwent significant changes in 2015, which has led to an increase in the number of drug approvals and subsequently drug launches in the country. The reforms in the Chinese drug regulatory system have had a significant impact on the new drug approval process and the median New Drug Application (NDA) approval time has been reduced to 15.4 months between 2017 and 2021, which is the shortest approval time in the last decade for China.

In the periods 2011 to 2013 and 2014 to 2016, the NDA approval time in China was 22.1 months and 35.1 months, respectively. Priority Review (PR) and Urgently Needed Overseas Drugs (UNOD) pathways have contributed to this improved efficiency, enabling faster access to the Chinese market. In this article, we delve into the impact of these changes and explore how Forecast Link, IQVIA's powerful syndicated forecasting tool, adapts to this evolving trend.

A launch lag analysis was carried out using IQVIA MIDAS data for the years 2012 to 2023 for innovative branded products to determine the delay of the launch of new drugs in any country when compared to their first global launch country (launch lag), measured in quarters. IQVIA MIDAS is a unique database that provides product volumes, trends and market share through retail and non-retail channels across the globe.2 Innovative branded products are the unique new international products that are non-generic in MIDAS. The data for innovative branded, non-generic prescription drugs with quarterly sales in any of the 75 countries listed in Forecast Link from 2012 to 2022 was extracted from MIDAS. The first global launch quarter and first country launch was determined from the first quarter of data with sales. The difference between the first global launch quarter and the respective country launch quarter was used to identify the launch lag. Corporations were tagged based on sales and headquarters to various categories and classified as company peersets. This was done to identify companies with similar facilities and opportunities for launch of products. The entire dataset was then split by country and company peersets, to determine the quarterly launch lag in China.

Download the article to learn about China's growth in product launches, reduce launch lag, launch timeline and more.

You may also be interested in

Case Study
Driving Global Impact in Ophthalmology Generics
Article
Orphan Drug Exclusivity: A Lifeline for Rare Disease Patients
Fact Sheet
IQVIA Patient Engagement Technology
Case Study
Improving Affordability, Access and Adherence with a Customized Patient Engagement Technology
Publication
IQVIA APAC Insight: Issue 11
White Paper
China: An Early Opportunity for Emerging Biopharma
Prev
Next

Related solutions

Contact Us